About Tubulin alpha chain-like 3
Tubulin alpha chain-like 3 (TUBAL3) is a protein
from Homo sapiens identified by UniProt accession
A6NHL2, 446 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Tubulin alpha chain-like 3 |
| UniProt accession | A6NHL2 |
| Gene | TUBAL3 |
| Organism | Homo sapiens |
| Length | 446 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (42)
Diseases linked to this target (Open Targets).
- viral disease · score 0.46
- head and neck squamous cell carcinoma · score 0.23
- esophageal cancer · score 0.23
- gastric adenocarcinoma · score 0.23
- breast adenocarcinoma · score 0.23
- triglyceride measurement · score 0.11
- sleep duration · score 0.09
- IGF-1 measurement · score 0.08
- sex hormone-binding globulin measurement · score 0.08
- alkaline phosphatase measurement · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NHL2-F1 | alphafold | PREDICTED | 90.89 | — |
Amino-acid sequence (446 residues)
MRECLSIHIG QAGIQIGDAC WELYCLEHGI QPNGVVLDTQ QDQLENAKME HTNASFDTFF CETRAGKHVP RALFVDLEPT VIDGIRTGQH RSLFHPEQLL SGKEDAANNY ARGRYSVGSE VIDLVLERTR KLAEQCGGLQ GFLIFRSFGG GTGSGFTSLL MERLTGEYSR KTKLEFSVYP APRISTAVVE PYNSVLTTHS TTEHTDCTFM VDNEAVYDIC HRKLGVECPS HASINRLVVQ VVSSITASLR FEGPLNVDLI EFQTNLVPYP RIHFPMTAFA PIVSADKAYH EQFSVSDITT ACFESSNQLV KCDPRLGKYM ACCLLYRGDV VPKEVNAAIA ATKSRHSVQF VDWCPTGFKV GINNRPPTVM PGGDLAKVHR SICMLSNTTA IVEAWARLDH KFDLMYAKRA FLHWYLREGM EEAEFLEARE DLAALERDYE EVAQSF
Explore Tubulin alpha chain-like 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets